NEW YORK (GenomeWeb News) – Microbiome company Second Genome today announced a deal with Johnson & Johnson's Janssen Biotech aimed at microbiome drug discovery.

Second Genome also announced it raised an additional $6.5 million in Series A financing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two recent papers published in Science and Nature Medicine describe work that may result in a universal vaccine for the flu.

In PNAS this week: The sea anemone is sequenced, a team describes a CRISPR/Cas9-based approach to label specific sites in the genome, and more. 

In a short video, CNN introduces viewers to a fecal transplant poop donor and explains how the treatments are made.

Researchers are testing the use of transgenically altered diamondback moths as an alternative to pesticides in controlling the bugs.